Research Article

Retrospective Study of Bone-TB in Oman: 2002–2019

Wael A.H. Hegazy,1,2,*, Raqiya Al Mamari,3 Khalfan Almazroui,3 Ali Al Habsi,1 Ahmed Kamona,2 Huda AlHarthi,3 Areej I. Al Lawati,4 AlZahra H. AlHusaini3

1Department of Microbiology and Immunology, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt
2Department of Pharmacy Practice and Pharmaceutical sciences, Pharmacy Program, Oman College of Health Sciences, Muscat, Sultanate of Oman
3Pharmacy and Medical Store Department, Clinical Pharmacy Section, Directorate General of Khoula Hospital, Muscat, Sultanate of Oman
4Department of Pharmacy Practice and pharmaceutical sciences, Pharmacy Program, Oman College of Health Sciences, Muscat, Sultanate of Oman

ABSTRACT

Objective: Little information is available about the etiology, pathophysiology, risk factors, and epidemiologic features of Bone Tuberculosis (Bone-TB). In this work, we present the epidemiological data about the Bone-TB in the Sultanate of Oman.

Methods: Retrospectively, we identified and assessed those patients who were diagnosed with Bone-TB between January 2002 and December 2019 at Khoula Hospital. The following data were collected: demographics, clinical presentation, anatomical location, diagnosis, and treatment of the Bone-TB.

Results: During the study period, 115 cases of Bone-TB were diagnosed. Males were affected more than females (57.4% and 42.6%, respectively). About 30% of Bone-TB cases were primary diagnosed in other organs particularly the lungs and then after disseminated to the bone. However, the Bone-TB was detected in hip, leg, hand, shoulder, and skull bones, the most detected location, diagnosis, and treatment of the Bone-TB.

Conclusion: The most predominant Bone-TB cases were spine-TB that were mainly disseminated from the lungs. AFS failed to detect tubercle bacilli in 40% of cases. There is no statistical significance in relapse between the used two regimens. The death was predominant among skull-TB cases.

1. INTRODUCTION

Tuberculosis (TB) is a major public health issue and is one of the top 10 causes of death from any infectious agent. According to the World Health Organization (WHO Global tuberculosis report, 2019 [1]), it infects around 10 million people worldwide. In 2018, WHO reported 1.2 million TB deaths globally with an extra 251,000 deaths among Human Immunodeficiency Virus (HIV) positive people. TB is a multisystem infectious disease; it can affect any tissue or organ, except the hair and nails [2]. TB is caused by Mycobacterium tuberculosis complex that causes chronic necrosis characterized by the formation of granulomatous lesions in the affected tissues [3]. The disease has two conditions: latent infection and active disease; active disease can be developed in approximately 10% of the infected patients [4].

Tuberculosis can infect any or all organs, however, lungs remain the most affected organ (85%) with Pulmonary Tuberculosis (PTB) being the most common TB with great epidemiological significance [3–5]. Extra-Pulmonary Tuberculosis (EPTB) includes TB that infects organs other than the lung parenchyma, such as the pleura, lymph nodes, skin, meninges, abdomen, gastrointestinal tract (GIT), genitourinary tract, joints, and bones [2,3]. The dissemination of TB to infect other organs extra-pulmonary depends on associated diseases, ethnicity, and compromised immune system [3,6]. Although the primary mycobacterial infections remain dormant without disease development, the suppressed immune system accelerates its reactivation [7–9]. As a consequence, the risk of EPTB increases with advancing immunosuppression. For instance, EPTB can be seen in more than 50% of patients with AIDS [10]. The increased incidence of EPTB lies to some extent in the difficulty of its diagnosis, resulting in a delay in diagnosis and severe sequelae [6,10,11].

Bone and joint TB is an ancient disease, osteoarticular-TB has been identified in Egyptian mummies [12,13], Europeans’ skeletons in the Middle Ages [14], and even earlier in Iron Age remains from Asia [15]. M. tuberculosis is the most common cause of mycobacterial osteomyelitis and arthritis [16]. Nontuberculous Mycobacterial (NTM) skeletal infections are usually associated with a previous puncture, injury, or with orthopedic surgery [16]. NTM is...
very rare but has increased with the increase in AIDS prevalence [17]. Recently, *Mycobacterium bovis* skeletal infections have been observed after intravesical therapy with Bacillus Calmette–Guérin (BCG) therapy [18,19]. According to WHO, in 2018, the incidence of TB in the Sultanate of Oman was estimated as 5.9 per 100,000 population and mortality rates of 0.37 per 100,000 population. Although there are many reports describing Bone Tuberculosis (Bone-TB) infections, and their increasing prevalence in developing countries [20–24]. There were few publications on TB and its elimination in Oman [25–30], and no publications on Bone-TB until the date of writing this work. In this report, we studied retrospectively Bone-TB cases in Oman referred from the whole country to Khoula hospital, in the period of 2002–2019. We investigated the demographics of the cases, the transmission and anatomical distribution of the disease, the diagnosis, and treatment regimens.

2. MATERIALS AND METHODS

This study was conducted at Khoula Hospital, Muscat, Sultanate of Oman, a tertiary care facility that was chosen as an educational center recognized by the Royal Society of Orthopedics and Neurosurgery. It is one of the distinguished health institutions in the provision of specialized health care and high quality in many fields including orthopedics, hand surgery, spinal surgery, and neurosurgery. A retrospective study was conducted to identify and assess those patients who were diagnosed with Bone-TB between January 2002 and December 2019. After receiving approval from the Institutional Review Board, we collected the patients’ data including demographics (age, sex, and nationality), patients’ histories, diagnosis, clinical presentation, anatomical location of Bone-TB, and treatment regimens. The collected data were entered into a spreadsheet and analyzed using GraphPad Prism 8 software.

3. RESULTS

3.1. Demographic Characteristics

During the study period, 115 cases from Muscat and other regions were diagnosed as Bone-TB cases (Figure 1). Generally, males were affected more than females (57.4% with average age 41.5 years and 42.6% with average age 32.5 years, respectively) (Figure 1A). The patients were distributed according to age and sex (Figure 1C), the highest diagnosed cases were in the age range of 19–40 years. Despite that about 88% of cases were Omani (Figure 1B), the higher number of diagnosed cases were observed in years 2015–2017 especially among expatriates from India (11th on TB burden countries list according to WHO Global tuberculosis report, 2019 [1]) (Figure 1D).

3.2. Bone-TB Transmission

The transmission of Bone-TB was represented in Figure 2. By taking patients’ histories, we found that 28.7% (33 out of 115 cases) of Bone-TB cases were primarily TB-diagnosed in other organs and then disseminated to bone (Figure 2B). Consequently, about 39% of pulmonary-TB cases were disseminated to infect bone, particularly spine bones. It was observed that 100% of testicular, fallopian, ovarian, and urinary tract-TB cases disseminated to Bone-TB. Meanwhile, seven out of nine (77.8%) CNS-TB diagnosed cases developed Bone-TB in later stages and one out of two (50%) lymph nodes-TB cases disseminated to the bone. Interestingly,

![Figure 1](image1.png)

**Figure 1** Demographic characteristics and the prevalence of Bone-TB cases. (A) The sex and average age of the cases. (B) The nationality of the cases. (C) The distribution of the cases according to age and sex. (D) The prevalence of cases in the period of 2002–2019.
seven cases (6.1%) were among the medical team who acquired TB-Bone from their continuous and unsafe contact with patients. Most of these cases (six out of seven cases) were primarily respiratory tract infected and then disseminated to the bone. In the same context, five patients (4.3%) acquire TB after accidental use of contaminated tools or after trauma which leads to dissemination of TB to bone. About 5% of cases acquired TB from long contact with their family members, which was primarily transmitted by droplets or using patients’ tools. Surprisingly, eight cases (7%) were infected by TB after BCG vaccine. It is worthy to mention that about 49% of cases were not previously diagnosed as TB cases and were diagnosed as Bone-TB for the first time with an unknown transmission method.

3.3. Anatomical Distribution of Bone-TB

The percentages of affected bones by TB were represented in Figure 3 and the detailed anatomical distribution was shown in Table 1 among male and female cases.

3.3.1. Spine-TB

Spine-TB was detected among 66% of cases. However, with a higher incident rate in males (41) compared to females (35), however, it was diagnosed at a younger age in females than males. It is more prevalent in dorsal and lumbar parts, while sacral and cervical vertebra were the least affected. Additionally, dorsal and sacroiliac-TB was observed in younger ages and TB in the dorsal-lumbar region was observed in higher Body Mass Index (BMI), especially among females. While sacroiliac-TB was observed only in females not males, TB in the dorsal-lumbar and cervical region is more prevalent in males than females. Kyphosis was observed in five cases, and 10% of cases were diagnosed with neurological deficits and needed surgical intervention in addition to drug treatment.

3.3.2. Hipbone-TB

This was more prevalent among young females (four out of six cases) than males. Moreover, it was observed in obese females
Phase 1: 2 months
Rifampicin 450 mg/OD

Phase 2: 10 months
Isoniazid 300 mg/OD
Ethambutol 1.2 g/OD

Phase 3: 6 months (two drugs + Vit. B6)
Isoniazid 300 mg/OD
Rifampicin 450 mg/OD

Table 2 The used treatment regimens

| Regimen 1 | Regimen 2 |
|-----------|-----------|
| Phase 1: 3 months (four drugs + Vit. B6) | Phase 1: 2 months (four drugs + Vit. B6) |
| Isoniazid 300 mg/OD | Isoniazid 300 mg/OD |
| Rifampicin 450 mg/OD | Rifampicin 450 mg/OD |
| Ethambutol 1.2 g/OD | Ethambutol 1.2 g/OD |
| Pyrazinamide 1.5 g/OD + Pyridoxine 20 mg/OD | Pyrazinamide 1.5 g/OD + Pyridoxine 20 mg/OD |
| Phase 2: 3 months (three drugs + Vit. B6) | Phase 2: 10 months (two drugs + Vit. B6) |
| Isoniazid 300 mg/OD | Isoniazid 300 mg/OD |
| Rifampicin 450 mg/OD | Rifampicin 450 mg/OD |
| Ethambutol 1.2 g/OD + Pyridoxine 20 mg/OD | |
| Phase 3: 6 months (two drugs + Vit. B6) | |
| Isoniazid 300 mg/OD | |
| Rifampicin 450 mg/OD | |

Nb 1. Phase 3 may be extended according to orthopedic surgeon recommendations. Nb 2. LFT routinely every 6 weeks. Nb 3. Dose was adjusted according to weight of patients. OD, once daily.
were considered as the direct cause of death in eight (6.95%) cases. Importantly, therapeutic approaches and/or surgical interventions failed to cure the five cases who were diagnosed skull-TB with a death rate of 100%.

### 3.6.1. Compliance to treatment regimens and relapse of TB

About 30% of patients did not comply with the used treatment regimens, the discontinuation of treatment was due to drugs’ and patients’ factors (Figure 4). The exaggerated side effects and resistance to TB drugs represented 44% and 29.5% of non-compliant patients, respectively. The serious patients’ health conditions due to major surgical operations or incapability to administrate the treatment was also reported in about 12% of non-compliant patients. Unfortunately, about 15% of non-compliant patients either did not follow or rejected to continue the treatment (Figure 4B). The compliance to each regimen did not vary greatly between the two regimens (68% and 71%, respectively) (Figure 4A and 4C). The most reported side effects to the prescribed medications were summarized in Table 3 and represented in each regimen in Figure 4D.

### 3.6.2. Relapse of TB and resistance development to anti-TB drugs

Relapse was observed in about 12.4% of total cases, with 9% and 14.5% of patients treated with two regimens respectively. Chi-square test (GraphPad Prism 8 software) was used to compare the relapse in the used two regimens. Chi-square was not statistically significant ($p = 0.45$); indicating that there was no significant difference in relapse in the used regimens. Interestingly, five out of 14 relapsed patients were compliant to treatment regimens, two of five cases were HIV patients. Among non-compliant patients, nine cases showed TB relapse, either due to drug resistance development

| Side effects                  | No. of cases | Notes                                      |
|------------------------------|--------------|--------------------------------------------|
| Gastritis/GIT disturbance    | 55           | Vomiting was observed in three cases       |
| Disturbed kidney functions   | 21           | Streptomycin-induced nephrotoxicity in one case |
| Elevated liver enzymes       | 19           | Isoniazid-induced hepatotoxicity in five cases, Pyrazinamide-induced hepatotoxicity in two cases |
| Anemia/lowed HB              | 20           | Lowered HB improved after stop of treatment |
| Skin rash                    | 4            | Relief by time                            |
| Otoxicity                    | 1            | Streptomycin-induced otoxicity in one case |
| Vision disturbance           | 2            | Ethambutol-induced visual disturbances and pain of eye in two cases below 7 years old |
| Seizures                     | 1            | Ethambutol-induced seizures in one case    |

Figure 4  Compliance to TB treatment used regimens. (A) Compliance to the used regimens and percentage of relapse. (B) The causes of non-compliance to used treatments. (C) The causes of non-compliance to each used regimen. (D) The most observed side effects in both regimens.
(three cases) or discontinuation of the treatment (six cases). While the pyrazinamide resistance was detected in six patients, the resistance to rifampicin was identified in three patients. Three of the identified BCG strains developed resistance to both pyrazinamide and rifampicin. Interestingly, one case was resistant to rifampicin, isoniazid, streptomycin, and kanamycin (Table 4).

### 4. DISCUSSION

Millions of people contract TB each year, making it a major public health issue globally. Despite the low numbers of TB cases in Oman (WHO Global tuberculosis report, 2019 [1]), the efficient documentation facilitates the follow-up by the medical teams. While, all TB complicated cases are referred to tertiary care centers as routine, Bone-TB cases are directed to Khoula hospital. In this study, we retrospectively reviewed all the referred Bone-TB cases (115 cases) from all of Oman to Khoula hospital.

Bone-TB was not greatly varied between males and females (57.5% and 42.5%, respectively); however, we observed the highest incidence of Bone-TB in ages 19–61 years and in females more than males. Following these observations, the highest TB rates were observed in ages between 25 and 64 years [31]. Although there is no real correlation between dissemination of TB and age reported, we can assume higher Bone-TB cases disseminated from other infected sites in immunocompromised elderly patients.

Surprisingly, Bone-TB was diagnosed in 10 babies below 2 years, and the isolated strains were of BCG strains. Moreover, the developed Bone-TB was detected anatomically near injection sites especially in the thigh region. Regional bone infections such as BCG osteomyelitis or osteitis and disseminated BCG infections are rare complications of BCG vaccination [32]. BCG vaccine should be intradermally injected, but if given subcutaneously, it may spread to the regional lymph nodes, causing either supplicative or nonsuppurative lymphadenitis [32]. On the other hand, cold abscesses are the most significant clinical presentation of the erroneous administration of the BCG vaccine when intramuscularly injected into the thigh [33].

Tuberculosis is an extremely contagious disease and can infect all organs. In the current study, we observed the dissemination of TB to infect bone in 57.5% of immunocompromised or chronic patients. PTB is the most common TB [5], Bone-TB was diagnosed in 40% of the referred PTB cases to Khoula hospital. However, 50% of the TB transmission to bone cases were not documented or traced, but we observed few Bone-TB cases in TB patient’s family members, among medical team co-workers, and even accidentally after trauma.

Bone-TB anatomical distribution was represented in detail (Table 1 and Figure 3). Pott’s disease is spinal tuberculosis, it spreads through hematogenous route from other sites, often the lungs. Pott’s disease is the most common extrapulmonary manifestation of TB associated with constitutional symptoms, tenderness, back pain, paraplegia, and sciotic or kyphotic deformities [16,34–36]. It accounts for 2% of all TB cases, 15% of EPTB, and 50% of skeletal-TB [34,36]. In compliance with these results, spine-TB was diagnosed in 66% of all Bone-TB cases. Moreover, most cases were detected in the dorsal-lumbar region, as an implication of hematogenous spread from the lungs. Furthermore, Bone-TB was diagnosed in the foot, hand, skull, hipbone, shoulder, and clavicle as is described in detail in the “Results” section.

The delayed or even missed diagnosis of EPTB in general and Bone-TB in particular is often owed to insidious clinical manifestations and/or poor performance of diagnostic tools [35,37–40]. However, culturing and AFC of Mycobacterium species are classical gold standards for TB diagnosis and technical and logistical restrictions in Bone-TB cases are increasingly recognized [39,40]. In the current work, AFC failed to diagnose 42% of cases because of the difficulty of sample collection or event failure in staining or culturing of the microbe. PCR is significantly used for an early diagnosis of EPTB, in spite of high variations in its results. However, there are different gene targets, IS6110 followed by 165 RNA genes encoding MPB-64 proteins are the most widely used gene targets [37]. Multiplex PCR, in which two or more genes are targeted, is used to diagnose many suspected cases, when conventional microbiological tests fail [19,37,41,42]. In this study, it was observed that all AFC negative cases were diagnosed by Multiplex PCR. Although the incapability of PCR to differentiate between viable and nonviable Mycobacterium, PCR results plus clinical diagnosis along with histopathology if affordable are adequate to initiate anti-TB treatment [19,34,37,38].

The Bone-TB is protracted through three stages over 3–5 years: onset, destruction, and the last stage of repair and ankyloses resulting in high morbidity and mortality [43,44]. Anti-TB chemotherapy achieved dramatic resolution of TB lesions. The chemotherapeutic treatment of TB is aimed to cure the individual patient, minimize the risk of death, decrease the transmission to other people and prevent the development of drug resistance during therapy course [44–46]. The resistance to anti-TB is a global health threat with increasing incidence worldwide [44]. Anti-TB resistance is developed when treatment regimens are not properly administered or adhered to, it occurs also as a result of biological variations in drug uptake or substandard drugs [44,47–49]. Multidrug-resistant (MDR) TB includes the resistance to at least two of the most effective anti-TB drugs, isoniazid, and rifampicin. Extensively Drug-resistant (XDR) TB involves an extra resistance to any fluoroquinolone and to any of the second line injectable anti-TB aminoglycosides (amikacin, capreomycin and kanamycin) [44,47].

Multidrug-resistant tuberculosis is an important public health problem and increasing rates are reported globally, in Oman the percentage of MDR-TB increased from 0% in 2017 to 2.9% in 2018 according to the WHO Global tuberculosis report, 2019 [1]. While the WHO Global tuberculosis report documents high resistance to rifampicin in Oman (≥16 data points) between 1995 and 2019, the resistance to rifampicin was detected in six (5.2%) of studied Bone-TB cases. Moreover, resistance to pyrazinamide has been observed in six patients and one case was XDR-TB. Over the period of study, two treatment regimens were used (Table 2).

### Table 4 The observed resistance to the used anti-TB drugs

| Drugs          | No. of resistant cases | Notes                                      |
|----------------|------------------------|--------------------------------------------|
| Pyrazinamide   | 6                      | Three out of six cases were BCG strains    |
| Rifampicin     | 3                      | One out of three cases was BCG strains     |
| Isoniazid      | 1                      | One case was resistant to rifampicin +     |
| Streptomycin   | 1                      | isoniazid + streptomycin + kanamycin       |
| Kanamycin      | 1                      |                                            |

While the WHO Global tuberculosis report documents high resistance to rifampicin in Oman (≥16 data points) between 1995 and 2019, the resistance to rifampicin was detected in six (5.2%) of studied Bone-TB cases. Moreover, resistance to pyrazinamide has been observed in six patients and one case was XDR-TB. Over the period of study, two treatment regimens were used (Table 2).
Importantly, about 30% of patients were non-compliant to applied regimens, mainly due to side effects particularly GIT disorders, resistance development, and patients’ attitudes or bad health situations. Interestingly, the second regimen was used as a modification to first regimen and there is no great difference between percentages of patients’ compliance to each regimen, the percentage of relapse in second regimen (14.5%) was higher than relapse to first regimen. The success of treatment of new and relapse cases in 2017 was 51% in Oman according to the WHO Global tuberculosis report, 2019 [1].

In this study, we recognized relapse in 12% of Bone-TB cases. The relapse was observed significantly in non-compliant patients. Furthermore, in this study, surgical intervention is an obligation when the neurological deficit has been observed [50,51], only 10% of cases needed surgical interventions. Despite the presence of all required data saved in electronic files since 2002; there are some limitations of this study. The most important is the difficulty to follow-up foreign patients who left Oman or patients who continue their treatment out of Oman.

In conclusion, we conducted this study to assess the epidemiology of Bone-TB in Oman. We retrospectively collected all the referred Bone-TB cases from the whole country. We found that the most predominant Bone-TB is spine-TB (66%), and mainly disseminated from the lungs. We documented the Bone-TB after vaccination with BCG vaccine in babies below 2 years old. However, AFS is considered the golden diagnostic test for TB, but it was not helpful in the diagnosis of 40% of cases because the difficulty of sample collection from bones or the scanty nature of the microbe itself; that is why PCR testing is mandatory for diagnosis and also for detection of resistance genes. It has been noticed that there is no significant difference in the relapse to the first older regimen and second newer regimen. Interestingly, all the patients who were diagnosed with TB in their skulls died, and treatment or surgical approaches were failed. It has been observed that the non-compliance of patients is mainly due to raised side effects and developed resistance to anti-TB drugs. However, GIT-related side effects are the most observed, kidney and liver function tests and blood pictures must be regularly performed. Monitoring of resistance development is crucial to avoid recurrences and relapses; in this study, the highest resistance was recognized to pyrazinamide (six cases) then rifampicin (three cases).

CONFLICTS OF INTEREST

The authors declare they have no conflicts of interest.

AUTHORS’ CONTRIBUTION

WAAH contributed in study conceptualization and writing (review & editing) the manuscript. RA, KA, AA, AK and WAAH contributed in data curation, formal analysis and writing (original draft). HA, AIA, AHA and WAAH contributed in funding acquisition and project administration. WAAH and RA supervised the project.

FUNDING

No financial support was provided.

REFERENCES

[1] WHO Global tuberculosis report. 2019. Geneva, Switzerland: WHO; 2019, pp. 15–20.
[2] Kulchavenya E. Extrapulmonary tuberculosis: are statistical reports accurate? Ther Adv Infect Dis 2014;2:61–70.
[3] Guler SA, Bozkus F, Inci MF, Kokoglu OE, Ucmak H, Ozden S, et al. Evaluation of pulmonary and extrapulmonary tuberculosis in immunocompetent adults: a retrospective case series analysis. Med Princ Pract 2015;24:75–9.
[4] Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. Am Fam Physician 2005;72:1761–8.
[5] Sharma SK, Mohan A, Sharma A. Miliary tuberculosis: a new look at an old foe. J Clin Tuberc Other Mycobact Dis 2016;3:13–27.
[6] Yang Z, Kong Y, Wilson F, Foxman B, Fowler AH, Marrs CF, et al. Identification of risk factors for extrapulmonary tuberculosis. Clin Infect Dis 2004;38:199–205.
[7] Carrol ED, Clark JE, Cant AJ. Non-pulmonary tuberculosis. Paediatr Respir Rev 2001;2:113–19.
[8] Hegazy WAH. Diclofenac inhibits virulence of Proteus mirabilis isolated from diabetic foot ulcer. Afr J Microbiol Res 2016;10:733–43.
[9] Askoura M, Youns M, Hegazy WAH. Investigating the influence of iron on Campylobacter jejuni transcriptome in response to acid stress. Microb Pathog 2020;138:103777.
[10] Lin JN, Lai CH, Chen YH, Lee SSJ, Tsai SS, Huang CK, et al. Risk factors for extra-pulmonary tuberculosis compared to pulmonary tuberculosis. Int J Tuberc Lung Dis 2009;13:620–5.
[11] Borand L, de Lauzanne A, Nguyen NL, Cheng S, Pham TH, Eyengoh S, et al. Isolation of nontuberculous mycobacteria in southeast Asian and African human immunodeficiency virus-infected children with suspected tuberculosis. Clin Infect Dis 2019;68:1750–3.
[12] Zink AR, Grabner W, Nerlich AG. Molecular identification of human tuberculosis in recent and historic bone tissue samples: the role of molecular techniques for the study of historic tuberculosis. Am J Phys Anthropol 2005;126:32–47.
[13] Chastel C. [When the Egyptian mummies are speaking about the infections that have made them ill]. Hist Sci Med 2004;38:147–55 [in French].
[14] Good RC, Snider DE. Isolation of nontuberculous mycobacteria in the United States, 1980. J Infect Dis 1982;146:829–33.
[15] Tayles N, Buckley HR. Leprosy and tuberculosis in Iron Age Southeast Asia? Am J Phys Anthropol 2004;125:239–56.
[16] Pigrau-Serrallach C, Rodriguez-Pardo D. Bone and joint tuberculosis. Eur Spine J 2013;22:556–66.
[17] Gardam M, Lim S. Mycobacterial osteomyelitis and arthritis. Infect Dis Clin North Am 2005;19:819–30.
[18] Jarzembowski JA, Young MB. Nontuberculous mycobacterial infections. Arch Pathol Lab Med 2008;132:1333–41.
[19] Nikaido T, Ishibashi K, Otani K, Yabuki S, Konno S, Mori S, et al. Mycobacterium bovis BCG vertebral osteomyelitis after intravesical BCG therapy, diagnosed by PCR-based genomic deletion analysis. J Clin Microbiol 2007;45:4085–7.
[20] Wang GC, Wu SW. Spinal intramedullary tuberculoma following pulmonary tuberculosis: a case report and literature review. Medicine (Baltimore) 2017;96:e8673.
[21] Wang L, Liu L, Song Y, Pei F, Liu H. Cervical tuberculosis associated with cervical pain and neurologic deficit: a case report and literature review. Spine J 2014;14:e13–e18.
[22] Moon MS. Tuberculosis of spine: current views in diagnosis and management. Asian Spine J 2014;8:97–111.
[23] Hogan JI, Hurtado RM, Nelson SB. Mycobacterial musculoskeletal infections. Thorac Surg Clin 2019;29;85–94.
[24] Hosalkar HS, Agrawal N, Reddy S, Sehgal K, Fox EJ, Hill RA. Skeletal tuberculosis in children in the Western world: 18 new cases with a review of the literature. J Child Orthop 2009;3;319–24.
[25] Al Awaidy ST. Tuberculosis elimination in Oman: winning the war on the disease. ERJ Open Res 2018;4;00121-2018.
[26] Al Yaquebi F, Al-Abri S, Al-Abri B, Al-Abaidani I, Al-Jardani A, D’Ambrosio L, et al. Tuberculosis elimination: a dream or a reality? The case of Oman. Eur J Public Health 2018;51;1702027.
[27] Al-Maniri A, Al-Rawas O, Al-Tuhami H, Eriksson B, Diwan VK. Towards the elimination of tuberculosis in a developing country: 25 years of tuberculosis control in Oman. Int J Tuberc Lung Dis 2007;11;175–80.
[28] Al-Maniri A, Fochsen G, Al-Rawas O, De Costa A. Immigrants and health system challenges to TB control in Oman. BMC Health Serv Res 2010;10;210.
[29] Al-Maniri AA, Al-Rawas OA, Al-Ajmi F, De Costa A, Eriksson B, Diwan VK. Tuberculosis suspicion and knowledge among private and public general practitioners: Questionnaire Based Study in Oman. BMC Public Health 2008;8;177.
[30] Khamis F, Al-Lawati A, Al-Zakwani I, Al-Abri S, Al-Naamani J, Al-Harthi H, et al. Latent tuberculosis in health care workers exposed to active tuberculosis in a tertiary care hospital in Oman. Oman Med J 2016;31;298–303.
[31] Mori T, Leung CC. Tuberculosis in the global aging population. Infect Dis Clin North Am 2010;24;751–68.
[32] Gharehdaghi M, Hassani M, Ghodsi E, Khooei A, Moayedpour A. Bacille Calmette-Guérin osteomyelitis. Arch Bone Jt Surg 2015;3;291–5.
[33] Al Namshan M, Oda O, Almaary J, Al Jadaan S, Crankson S, Al Banyan E, et al. Bacillus Calmette-Guérin-related cold thigh abscess as an unusual cause of thigh swelling in infants following BCG vaccine administration: a case series. J Med Case Rep 2011;5;472.
[34] Ansari S, Amanullah MF, Ahmad K, Rauniyar RK. Pott’s spine: diagnostic imaging modalities and technology advancements. N Am J Med Sci 2013;5;404–11.
[35] Malhotra HS. Diagnostic imaging in pott’s disease of the spine. N Am J Med Sci 2013;5;412–13.
[36] Jain AK, Kumar J. Tuberculosis of spine: neurological deficit. Eur Spine J 2013;22;624–33.
[37] Mehta PK, Raj A, Singh N, Khuller GK. Diagnosis of extrapulmonary tuberculosis by PCR. FEMS Immunol Med Microbiol 2012;66;20–36.
[38] Colmenero JD, Ruiz-Mesa JD, Sanjuan-Jimenez R, Sobrino B, Morata P. Establishing the diagnosis of tuberculous vertebral osteomyelitis. Eur Spine J 2013;22;579–86.
[39] Norbis L, Alagna R, Tortoli E, Codecasa LR, Migliori GB, Cirillo DM. Challenges and perspectives in the diagnosis of extrapulmonary tuberculosis. Expert Rev Anti Infect Ther 2014;12;633–47.
[40] Merino P, Caneld FJ, Gestoso I, Baos E, Picazo J. Microbiological diagnosis of spinal tuberculosis. Int Orthop 2012;36;233–8.
[41] Hegazy WAH, Henawy MA. Hepatitis C virus pathogenesis: serum IL-33 level indicates liver damage. Afr J Microbiol Res 2015;9;1386–93.
[42] Abd El-Hamid MI, El-Naenaeey EY, Kandeel TM, Hegazy WAH, Mosbah RA, Nasser MS, et al. Promising Antituberculosis drug: recent breakthrough against biofilm producing meticillin-resistant Staphylococcus aureus. Antibiotics (Basel) 2020;9:667.
[43] Rajasekaran S, Khandelwal G. Drug therapy in spinal tuberculosis. Eur Spine J 2013;22;587–93.
[44] Suárez-Garcia I, Noguerado A. Drug treatment of multidrug-resistant osteoarticular tuberculosis: a systematic literature review. Int J Infect Dis 2012;16;e774–e8.
[45] Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009;13;1320–30.
[46] Abbas HA, Hegazy WAH. Repurposing anti-diabetic drug “Sitagliptin” as a novel virulence attenuating agent in Serratia marcescens. PLoS One 2020;15:e0231625.
[47] Mandal N, Anand PK, Gautam S, Das S, Hussain T. Diagnosis and treatment of paediatric tuberculosis: an insight review. Crit Rev Microbiol 2017;43;466–80.
[48] Soundararajan DCR, Rajasekaran RB, Rajasekaran S, Shetty AP, Kanna RM. Drug-resistant spinal tuberculosis – current concepts, challenges, and controversies. J Clin Orthop Trauma 2020;11;863–70.
[49] Yang S, Yu Y, Ji Y, Luo DJ, Zhang ZY, Huang GP, et al. Multi-drug-resistant spinal tuberculosis-epidemiological characteristics of in-patients: a multicentre retrospective study. Epidemiol Infect 2020;148:e11.
[50] Li DW, Ma YZ, Hou Y, Xue HB, Huang FS. [Surgical treatment of drug-resistant spinal tuberculosis]. Zhongguo Gu Shang 2010;23;485–7 [in Chinese].
[51] Mak KC, Cheung KMC. Surgical treatment of acute TB spondylitis: indications and outcomes. Eur Spine J 2013;22;603–11.